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2ABSTRACT  14 
Micro-hydrogels are very promising systems for the protection and controlled delivery of 15 
sensitive bioactives, but limited knowledge exists regarding the impact of this encapsulation on 16 
their bioaccessibility. In this work, two different hydrogel-forming biopolymers (gelatin and 17 
chitosan) were compared as wall materials for the microencapsulation of a model flavonoid, (Ð)-18 
epigallocatechin gallate (EGCG). Results showed that gelatin was more adequate as wall 19 
material for the encapsulation of EGCG than chitosan, achieving higher encapsulation 20 
efficiencies (95% ± 6%), being more effective in delaying EGCG release and degradation in 21 
aqueous solution and exhibiting a 7 times higher bioaccessibility of the bioactive compound (in 22 
terms of antioxidant activity) after in-vitro gastrointestinal digestion. A very low bioaccessibility 23 
of EGCG in chitosan was observed, due to the neutralization of the carbohydrate in the basic 24 
simulating salivary conditions, thus precluding subsequent flavonoid release. Moreover, gelatin 25 
micro-hydrogels also hindered dimer formation during in-vitro digestion, thus suggesting greater 26 
bioavailability when compared with free EGCG.  27 
28 
29 
30 
KEYWORDS  31 
Microencapsulation; gelatin; chitosan; flavonoids; EGCG; bioaccessibility 32 
33 
34 
35 
36 
31. INTRODUCTION 37 
The development of functional biopolymer nanoparticles or microparticles as 38 
encapsulation and delivery systems has enjoyed a great deal of interest in diverse academic fields 39 
such as foods, pharmaceutics or cosmetics, highlighting the potential of these structures to 40 
protect sensitive bioactives against degradation (Jones & McClements, 2011). Amongst the wide 41 
range of bioactive substances studied, green tea flavonoids are powerful antioxidants which have 42 
drawn much research attention because of their many attributed therapeutic benefits (Fu et al., 43 
2011; Larsen & Dashwood, 2009, 2010; Singh, Shankar, & Srivastava, 2011; Singh, Akhtar, & 44 
Haqqi, 2010; Steinmann, Buer, Pietschmann, & Steinmann, 2013), being (Ð)-epigallocatechin 45 
gallate (EGCG) the most abundant polyphenol in green tea possessing the greatest biological 46 
activity (Barras et al., 2009). However, EGCG is sensitive to heat (Wang, Zhou, & Wen, 2006), 47 
oxygen (Valcic, Burr, Timmermann, & Liebler, 2000) and light (Scalia, Marchetti, & Bianchi, 48 
2013) and, in general, chemically unstable (Dube, Ng, Nicolazzo, & Larson, 2010a), especially 49 
in aqueous solutions (Dube, Nicolazzo, & Larson, 2010b; Li, Lim, & Kakuda, 2009). Thus, 50 
encapsulation of this bioactive compound has been widely explored to improve its stability 51 
during food processing and storage (Dube et al., 2010b; Fang & Bhandari, 2010; Gómez-52 
Mascaraque, Lagarón, & López-Rubio, 2015; Li et al., 2009; Shutava, Balkundi, & Lvov, 2009a; 53 
Shutava et al., 2009b). Several techniques have been explored for this purpose, being costs and 54 
the use of food permitted solvents and matrices the limiting factors for the practical use of 55 
encapsulation structures in functional food applications. In this sense, spray-drying is the most 56 
widely used encapsulation technique in the food industry (Jiménez-Martín, Gharsallaoui, Pérez-57 
Palacios, Carrascal, & Rojas, 2014), as it is a straightforward and cheap procedure which allows 58 
the processing of a wide range of food-grade materials with accessible equipment (Gharsallaoui, 59 
4Roudaut, Chambin, Voilley, & Saurel, 2007). This technique involves the initial atomization of a 60 
formulation containing the wall matrix and the bioactive into fine droplets, followed by their 61 
rapid drying using a hot gas stream, which leads to solvent evaporation and rapid formation of 62 
the microparticles. Regarding the encapsulation matrices, food-grade biopolymers capable of 63 
forming physical hydrogels are of particular interest. Physical hydrogels are polymer networks 64 
characterized by the presence of physical crosslinks, entanglements and/or rearrangements of 65 
hydrophobic and hydrophilic domains (Gómez-Mascaraque, Méndez, Fernández-Gutiérrez, 66 
Vázquez, & San Román, 2014). Thus, hydrogel-forming biopolymers can be processed in 67 
aqueous solutions, while preventing dissolution of the obtained microparticles in aqueous foods 68 
under certain conditions.  While the protection exerted by the microparticles has obvious benefits 69 
during the commercialization stage, an important aspect is the bioaccessibility of the functional 70 
compounds after ingestion, as it has been recently observed that encapsulation may decrease it to 71 
a certain extent (Roman, Burri, & Singh, 2012). Another desirable property of potential 72 
encapsulating materials for the protection of EGCG is their processability in acidic pHs, as this 73 
antioxidant molecule exhibits higher stability in acidic media (Dube et al., 2010a; Shpigelman, 74 
Cohen, & Livney, 2012). Chitosan and gelatin are two edible, naturally-derived biopolymers 75 
satisfying both requirements.  76 
Chitosan is a linear polysaccharide obtained by deacetylation of naturally occurring chitin 77 
and consists of -1,4 linked 2-acetamido-2-deoxy--D-glucopyranose units and 2-amino-2-78 
deoxy-b-D-glucopyranose units in a proportion which depends on the degree of deacetylation of 79 
chitin (Khor & Lim, 2003) (cf. Figure 1). Chitosan is soluble in acidic aqueous solutions, where 80 
its amino groups are protonated, but gels at neutral or alkaline solutions because of the strong 81 
intermolecular interactions, being considered a pH-sensitive hydrogel (Lim, Hwang, Kar, & 82 
5Varghese, 2014). Several beneficial properties such as antimicrobial activity (Kong, Chen, Xing, 83 
& Park, 2010), lipid-lowering effects (Kerch, 2015), and wound healing (Ueno et al., 1999) have 84 
been attributed to this polysaccharide, which has been previously used to stabilize EGCG in 85 
nanoparticles by the ionic gelation method with tripolyphosphate (Dube et al., 2010a; Dube et 86 
al., 2010b). Through spray-drying, it has also been used to successfully encapsulate other 87 
polyphenolic extracts like olive leaf extract (Kosaraju, D'ath, & Lawrence, 2006) or yerba mate 88 
extract (Harris, Lecumberri, Mateos-Aparicio, Mengíbar, & Heras, 2011). 89 
Gelatin is a protein obtained from partial hydrolysis of naturally occurring collagen and 90 
contains repeating sequences of glycine-aa1-aa2, where amino acids aa1 and aa2 are mainly 91 
proline and hydroxyproline (Lai, 2013) (cf. Figure 1). Gelatin forms thermoreversible hydrogels 92 
in aqueous solutions due to the formation of collagen-like triple helices below the so-called 93 
helixÐcoil transition temperature, leading to chains entanglement and subsequent network 94 
formation (Peña, de la Caba, Eceiza, Ruseckaite, & Mondragon, 2010) and, thus, it is considered 95 
as a thermo-responsive hydrogel-forming biopolymer. Gelatin has been traditionally used for the 96 
production of macro-capsules by the pharmaceutical industry (Roussenova et al., 2012), and 97 
more recently as a microencapsulation material. Particularly, gelatin has been previously used to 98 
protect EGCG in microcapsules produced by layer-by-layer assembly (Shutava et al., 2009a; 99 
Shutava et al., 2009b), coacervation in combination with different polysaccharides (Fang et al., 100 
2010) or by electrospraying (Gómez-Mascaraque et al., 2015). Through spray-drying, it has also 101 
been used to microencapsulate other flavonoids like naringin (Sansone, Aquino, Gaudio, 102 
Colombo, & Russo, 2009).      103 
In the present work, spray-dried edible micro-hydrogels based on the polysaccharide 104 
chitosan and the protein gelatin were produced and used to microencapsulate EGCG as a model 105 
6flavonoid antioxidant. The suitability of both matrices, derived from natural polymers and 106 
capable of forming pH-sensitive and thermo-responsive hydrogels, respectively, to encapsulate 107 
EGCG was compared for the first time in terms of bioactive release, encapsulation efficiency and 108 
bioaccessibility of EGCG using the same processing technique, i.e. spray-drying. The 109 
bioaccessibility of EGCG after in-vitro gastrointestinal digestion of the capsules was also 110 
evaluated. Finally, the ability of the selected encapsulation matrix to protect EGCG against 111 
degradation in aqueous solutions was assessed. 112 
113 
INSERT FIGURE 1 ABOUT HERE 114 
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2. EXPERIMENTAL SECTION 116 
2.1. Materials 117 
Type A gelatin from porcine skin (Gel), with reported gel strength of 175 g Bloom, low 118 
molecular weight chitosan (Ch), with reported Brookfield viscosity of 20.000 cps, (Ð)-119 
epigallocatechin gallate (EGCG), 2,2-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) 120 
diammonium salt (ABTS), potassium persulfate (K2O8S2), buffer solutions of pH 7.4 (phosphate 121 
buffered saline system, PBS) and pH 6.1 (2-(N-morpholino)ethanesulfonic acid hemisodium salt, 122 
MES), potassium bromide FTIR grade (KBr), pepsin from porcine gastric mucosa, pancreatin 123 
from porcine pancreas and bile extract porcine were obtained from Sigma-Aldrich. Acetic acid 124 
(96% v/v) was purchased from Scharlab and Pefabloc® from Fluka. All inorganic salts used for 125 
the in-vitro digestion tests were used as received.  126 
7Acetonitrile and methanol were supplied by Merck (Darmstadt, Germany). Deionized 127 
water (>18 M cm-1 resistivity) was purified using Milli-Q® SP Reagent water system plus 128 
from Millipore Corp. (Bedford, USA). All solvents were passed through a 0.45 µm cellulose 129 
filter purchased from Scharlau (Barcelona, Spain). Analytical grade reagent formic acid (purity > 130 
98%) was obtained from Panreac Quimica S.A.U. (Barcelona, Spain). 131 
132 
2.2. Preparation of biopolymer microparticles 133 
Gelatin stock solutions with a concentration of 10% (w/v) were prepared by dissolving 134 
the protein in acetic acid 20% (v/v) at 40 ºC under magnetic agitation. The stock solutions were 135 
then cooled down to room temperature and further diluted 50-fold in distilled water before 136 
processing. 137 
Chitosan stock solutions with a concentration of 2% (w/v) were prepared by dissolving 138 
the polysaccharide in acetic acid 20% (v/v) at room temperature under magnetic agitation. The 139 
stock solutions were further diluted 50-fold in distilled water before processing. 140 
When EGCG was incorporated for its encapsulation, it was added to the corresponding 141 
biopolymer stock solutions at room temperature under magnetic stirring, at a concentration of 10 142 
(w/w) of the total solids content. 143 
The biopolymer solutions were fed to a Nano Spray Dryer B-90 apparatus (Büchi, 144 
Switzerland) equipped with a 7.0 µm pore diameter cap. The inlet air temperature was set at 90 145 
ºC, as it proved to be enough to achieve complete drying of the particles at an inlet air flow of 146 
146 ± 4 L/min and a reduced pressure of 50 ± 3 mbar. Under these conditions, the outlet air 147 
temperature varied between 44 and 50 ºC. The spray-dried powders were deposited on the 148 
collector electrode by means of an applied voltage of 15 kV. 149 
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2.3. Characterization of the microparticles 151 
Scanning electron microscopy (SEM) was conducted on a Hitachi microscope (Hitachi S-152 
4100) at an accelerating voltage of 10 kV and a working distance of 9-16 mm. Samples were 153 
sputter-coated with a gold-palladium mixture under vacuum prior to examination. Particle 154 
diameters were measured from the SEM micrographs in their original magnification using the 155 
ImageJ software. Size distributions were obtained from a minimum of 200 measurements. 156 
The particle size distributions of the spray-dried powders were determined by laser 157 
difraction using a Malvern Mastersizer 2000 apparatus equipped with 4 mW He-Ne (632.8 nm) 158 
and 0.3 mW LED (470 nm) light sources. The samples were suspended in ethanol to limit 159 
swelling of the particles and ultrasonicated to prevent aggregation.  160 
Empty and bioactive-containing capsules of ca. 1 mg were grounded and dispersed in 130 161 
mg of spectroscopic grade potassium bromide (KBr). A pellet was then formed by compressing 162 
the sample at ca. 150 MPa. FT-IR spectra were collected in transmission mode using a Bruker 163 
(Rheinstetten, Germany) FT-IR Tensor 37 equipment. The spectra were obtained by averaging 164 
10 scans at 1 cm-1 resolution. The microencapsulation efficiency (MEE) of the EGCG-loaded 165 
capsules was determined based on FTIR absorbance measurements. Calibration curves (RGel2 = 166 
0.995 and RCh2 = 0.999) were obtained using Gel/EGCG and Ch/EGCG physical mixtures, 167 
respectively, of known relative concentrations (0, 5, 10 and 15 % w/w of EGCG). For the 168 
Gel/EGCG calibration curve, the relative maximum absorbances at 1409 cm-1 (corresponding to 169 
gelatin) and 1039 cm-1 (attributed to EGCG) were plotted against the EGCG concentration in the 170 
mixtures. For the Ch/EGCG calibration curve, the relative maximum absorbances at 2885 cm-1171 
(corresponding to chitosan) and 1223 cm-1 (attributed to EGCG) were used. The EGCG content 172 
9in the capsules was interpolated from the obtained linear calibration equations, and the MEE of 173 
the systems was then calculated using Eq. (1): 174 
175  %  	
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Thermogravimetric analysis (TGA) was performed with a TA Instruments model Q500 178 
TGA. The samples (ca. 8 mg) were heated from room temperature to 600 ºC with a heating rate 179 
of 10 ºC/min under dynamic air atmosphere. Derivative TG curves (DTG) express the weight 180 
loss rate as a function of temperature. 181 
182 
2.4. In-vitro EGCG release from the micro-hydrogels 183 
Ten milligrams of EGCG-loaded particles were suspended in 20 mL of release medium 184 
(MES aqueous buffer, pH = 6.1) and kept at 20 ºC under agitation at 60 U/min in a Selecta 185 
thermostatic bath model Unitronic Reciprocal C (Barcelona, Spain). At different time intervals, 186 
the suspensions were centrifuged at 2547 g and room temperature during 10 min using a 187 
centrifuge from Labortechnik model Hermle Z 400 K (Wasserburg, Germany), and 1 mL aliquot 188 
of the supernatant removed for sample analysis. The aliquot volume was then replaced with fresh 189 
release medium and the particles resuspended and left back in the thermostatic bath. 190 
The extracted aliquots were analyzed by UV-vis spectroscopy (Shanghai Spectrum model 191 
SP-2000UV, Shanghai, China) by measuring the absorbance at 274 nm (maximum of absorbance 192 
of EGCG). Calibration curves for EGCG quantification in MES solution by UV-vis absorbance 193 
were previously obtained (R2 = 0.999). The EGCG release values were obtained from three 194 
independent experiments at the same conditions.   195 
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Experimental data were fitted to the Peppas-Sahlin semi-empirical model, whose general 196 
equation is Eq. 2, where Mt is the mass of EGCG released at time t, M0 is the total mass of 197 
EGCG loaded in the particles, ki are kinetic constants, and m is the Fickian diffusional exponent 198 
(Siepmann & Peppas, 2012).  199 
200                 Eq. (2) 201 
202 
2.5. Antioxidant activity of EGCG-containing micro-hydrogels 203 
ABTS+ radical scavenging assay was performed in order to quantify the antioxidant 204 
activity of both free and encapsulated EGCG, following the decolorization assay protocol 205 
described in a previous work (Gómez-Mascaraque et al., 2015). Briefly, a stock solution of 206 
ABTS+ was prepared by reacting ABTS with potassium persulfate (7 and 2.45 mM in distilled 207 
water, respectively) and allowing the mixture to stand in the dark at room temperature for 24 h. 208 
The ABTS+ stock solution was then diluted with acetic acid 20% v/v to an absorbance of 209 
0.70±0.02 at 734 nm. Stock solutions of free and encapsulated EGCG (5 mM of EGCG in all 210 
cases) were prepared in acetic acid 20% v/v and subsequently diluted 20-fold. 10 L of diluted 211 
sample solution were added to 1 mL of diluted ABTS+, and the absorbance at 734 nm was 212 
measured 1 min after initial mixing. The radical scavenging activity (RSA), expressed as the 213 
percentage of reduction of the absorbance at 734 nm after sample addition, was calculated using 214 
Eq. (3): 215 
216 
RSA %  -  100        Eq. (3) 217 
218 
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where A0 and A1 are the absorbances at 734 nm of ABTS+ before and 1 min after 219 
addition of the antioxidant samples, respectively.  220 
Experiments were performed on a Shanghai Spectrum spectrophotometer model SP-221 
2000UV (Shanghai, China), at least in triplicate. Solvent blanks were also run in each assay. The 222 
unloaded gelatin and chitosan particles were also evaluated (same particle mass concentration as 223 
for loaded samples) to take into account the potential antioxidant activity of the encapsulation 224 
matrices. 225 
226 
2.6. In-vitro gastrointestinal (GI) digestion and bioaccessibility assessment 227 
Suspensions (40 mg/mL) of the EGCG-containing microcapsules and solutions (4 228 
mg/mL) of free EGCG in distilled water were subjected to in-vitro GI digestion following to the 229 
standardized static in-vitro digestion protocol developed within the framework of the Infogest 230 
COST Action (Minekus et al., 2014). Solutions of simulated salivary fluid (SSF), simulated 231 
gastric fluid (SGF), and simulated intestinal fluid (SIF) were prepared according to the 232 
harmonized compositions (Minekus et al., 2014). In the oral phase, the suspensions were mixed 233 
with SSF (50:50 v/v) and incubated at 37 ºC for 2 min under agitation in a thermostatic bath. In 234 
the gastric phase, the oral digesta was mixed with SGF (50:50 v/v) and porcine pepsin (2000 235 
U/mL), and incubated at 37 ºC for 2 h under agitation. In the duodenal phase, the gastric digesta 236 
was mixed with SIF (50:50 v/v), porcine bile extract (10 mM) and porcine pancreatin (100 U/mL 237 
of trypsin activity), and incubated at 37 ºC for 2 h under agitation. The pH was adjusted to 7, 3, 238 
and 7 in the oral, gastric and duodenal phases, respectively, using 1M HCl or 1M NaOH 239 
solutions. After the duodenal phase, the protease inhibitor Pefabloc® (1 mM) was added. 240 
Aliquots were collected after the gastric and the duodenal phases and snap-frozen in liquid 241 
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nitrogen immediately. The antioxidant activity of the digestas was estimated after centrifugation 242 
by means of the ABTS+ assay, as an indirect assessment of the bioaccessibility of EGCG after 243 
digestion. HPLC-MS was also used to analyze the digestas. The LC system used for this analysis 244 
was an Agilent 1290 HPLC system. Separation of EGCG was performed using an Acquity BEH 245 
C18 (Waters, 50 mm × 2.1 mm, 1.7 µm of particle size) LC-column. The flow rate was set to 0.4 246 
mL/min and the oven temperature was 30 ºC, being eluent A water slightly acidified with 0.1% 247 
of formic acid, and eluent B methanol slightly acidified with 0.1% of formic acid. The elution 248 
gradient started with 5% of eluent B during 2 min, increasing to 95% B in 11 min. The injection 249 
volume was 10 µl. A Triple TOF 5600 system with a DuoSprayTM source operating in the 250 
negative ESI mode was used for detection (AB SCIEX, CA, USA). The following parameter 251 
settings were used: ion spray voltage, - 4500 ISVF; ion source heater, 400 °C ; curtain gas, 25 252 
psi; ion source gas 1.50 - 2.50 psi. For the full MS-IDA (information dependent acquisition) 253 
MS/MS analysis, the full MS, the survey scan, and the MS/MS experiments were run in positive 254 
mode with a scan range from m/z 100 to m/z 800 and a 250 ms accumulation time for the full 255 
MS. The declustering potential was -150 eV and collision energy was -77 eV. The MS was using 256 
an IDA acquisition method with two experiments: the survey scan type (TOF-MS) and the 257 
dependent scan type (product ion). Data was evaluated using the XIC manager in the 258 
PeakViewTM software.   259 
260 
2.7. Protection ability of gelatin spray-dried microhydrogels   261 
The ABTS+ assay was also used to evaluate the ability of the selected gelatin micro-262 
hydrogels to protect EGCG from degradation in aqueous media. For this purpose, the antioxidant 263 
activity of free and encapsulated EGCG was measured after dissolution/suspension in PBS. 264 
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Solutions (5 mM) of EGCG in PBS were prepared. Suspensions of EGCG-loaded capsules in 265 
PBS with theoretical EGCG concentrations of 5 mM were also prepared. After specific time 266 
intervals, the solutions/suspensions were diluted 20-fold with acetic acid 20% v/v and their RSA 267 
was calculated using eq. (2), after conducting the ABTS•+ assay. 268 
In order to confirm the results obtained from the degradation assays, HPLC-MS was also 269 
used to analyze the samples as described before. 270 
271 
2.8. Statistical analysis   272 
A statistical analysis of experimental data was performed using IBM SPSS Statistics 273 
software (v.23) (IBM Corp., USA). Significant differences between homogeneous sample groups 274 
were obtained through two-sided t-tests (means test of equality) at the 95% significance level (p 275 
< 0.05). For multiple comparisons, the p-values were adjusted using the Bonferroni correction. 276 
277 
3. RESULTS AND DISCUSSION 278 
3.1. Characterization of EGCG-loaded spray-dried biopolymeric microparticles 279 
Spray-dried powders were produced from a protein (Gel) and from a polysaccharide 280 
(Ch), both derived from naturally occurring biopolymers, and both leading to micro-hydrogels 281 
upon hydration in aqueous media. It is important to remark that the solutions were processed at 282 
considerable lower temperatures than those described in other works for the production of 283 
EGCG-loaded spray-dried biopolymeric particles (Peres et al., 2011), minimizing the 284 
degradation of the bioactive molecule when present.  285 
The morphology of the obtained powders is shown in Figure 2. Pseudo-spherical particles 286 
were observed, but different morphologies could be distinguished. Some particles exhibited a 287 
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corrugated surface, while others revealed a smooth surface. These two types of morphology have 288 
been previously described for spray-dried particles obtained from aqueous solutions (De Cicco, 289 
Porta, Sansone, Aquino, & Del Gaudio, 2014; Fu et al., 2011; Kusonwiriyawong, Lipipun, 290 
Vardhanabhuti, Zhang, & Ritthidej, 2013). Interestingly, a third morphology was also observed 291 
only in the gelatin samples, where concave and considerably bigger particles were also 292 
generated. This shape is typical of the so-called ‘ballooning’ effect which occurs at high drying 293 
rates when the polymeric matrix is elastic enough to enable this dents formation due to the 294 
thermal expansion of air or water vapors inside the drying particles, before solidification of the 295 
matrix (Peres et al., 2011). 296 
297 
INSERT FIGURE 2 ABOUT HERE 298 
299 
The particle size distributions of the spray-dried powders, determined by laser diffraction, 300 
are shown in Figure 3. The results were in agreement with the particle sizes observed in Figure 2, 301 
and showed that Gel provided significantly bigger microparticles than Ch. This might be due to 302 
differences in the packing structure and density of the two polymers, but also to the lower 303 
polymer concentration in the Ch solutions, owing to the high viscosity of this polysaccharide. 304 
The polydispersity was also lower for microparticles made of Ch. For Gel, the ‘ballooning’ effect 305 
resulted in some particles being substantially bigger than others. Nevertheless, the apparent 306 
bimodal distribution observed for this sample was attributed to multi-particle aggregation, as 307 
particles having sizes about 100 µm were not observed at all in the SEM micrographs. The 308 
EGCG-loaded particles showed similar morphologies and particle size distributions as compared 309 
to their unloaded counterparts. 310 
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INSERT FIGURE 3 ABOUT HERE 312 
313 
The presence of absorption bands attributed to EGCG in the infrared spectra of the loaded 314 
particles (cf. Figure 4), specifically the bands at 1042 cm-1 (which shifted to 1037 cm-1 in the 315 
capsules) and 1148 cm-1 for gelatin and the spectral band at 1223 cm-1 for chitosan, evidenced the 316 
presence of the bioactive molecule in the spray-dried capsules and allowed the estimation of the 317 
microencapsulation efficiency (MEE) of the system, prior construction of a calibration curve 318 
using physical mixtures of spray-dried biopolymers and EGCG of known relative concentrations 319 
(R2 = 0.995 and 0.999 for Gel and Ch, respectively). For this purpose, the relative absorbances of 320 
the bands at 1042 or 1223 cm-1 (EGCG) and 1409 cm-1 (Gel) or 2885 cm-1 (Ch) were plotted 321 
against the EGCG concentration in the mixtures.  322 
323 
INSERT FIGURE 4 ABOUT HERE 324 
325 
The MEE of the EGCG-loaded capsules was 95% ± 6% and 82% ± 9% for Gel and Ch, 326 
respectively. These high encapsulation efficiency values can be explained considering the great 327 
solubility of EGCG in the feed solutions and Moreover, the EGCG-loaded particles experienced 328 
some shifts of their infrared bands with respect to the components alone, such as the amide III 329 
band of gelatin which moved to 1240 cm-1 or the displacement of the Amide I band of Ch to 330 
lower wavenumbers, suggesting intermolecular interactions between the antioxidant molecule 331 
and the protective matrices, fact which is not surprising in the case of Gel as proteins and 332 
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polyphenols are known to form soluble complexes (Siebert, Troukhanova, & Lynn, 1996).the 333 
absence of partitioning effects (Dube et al., 2010b).  334 
The thermogravimetric (TG) profiles of pristine materials and their corresponding spray-335 
dried particles, both unloaded and EGCG-loaded, were analyzed to ascertain possible 336 
thermostability changes of the ingredients upon processing. The main results are summarized in 337 
Table 1 and Supplementary Figure S1. 338 
339 
Table 1. Onset temperature (Tonset), temperatures of maximum degradation rate (Tmax1 and Tmax2) and 340 
corresponding weight losses (WL1 and WL2) of the two main degradation stages for the raw materials and 341 
the spray-dried particles 342 
Sample Tonset (ºC) Tmax1 (ºC) WL1 (%) Tmax2 (ºC) WL2 (%)
EGCG 228.8 235.4 33.7 483.9 62.3
Gel 265.6 301.3 45.2 537.7 36.9
Ch 268.9 293.5 53.8 542.7 40.4
Spray-dried Gel 244.0 267.0/332.2 62.2 534.9 31.9
Spray-dried Gel+EGCG 238.1 268.7/329.3 65.53 518.4 32.1
Spray-dried Ch 218.1 257.8 62.1 458.4 25.76
Spray-dried Ch+EGCG 222.6 262.3 59.0 471.9 28.5
343 
No peaks attributable to the degradation of EGCG were detected in the DTG curves of 344 
the EGCG-loaded particles. This might be due to the good compatibility and molecular 345 
interactions between the antioxidant molecule and the biopolymeric matrices (as suggested by 346 
FTIR), which delayed the thermal degradation of EGCG until the integrity of the encapsulating 347 
materials was lost. 348 
349 
3.2. EGCG release from the micro-hydrogels 350 
The release of EGCG was evaluated upon hydration of the spray-dried particles in MES 351 
aqueous buffer (pH = 6.1) as a simulant for slightly acidic aqueous foods such as some juices 352 
(Tola & Ramaswamy, 2014). Figure 5 shows an initial burst release from both chitosan and 353 
gelatin micro-hydrogels, which was more abrupt for the chitosan matrix. The release from the 354 
17
gelatin capsules was noticeably more sustained in the initial hours. While the maximum release 355 
from chitosan was observed within the first 10 hours, the maximum EGCG release from gelatin 356 
was attained more than 5 times later, suggesting that gelatin micro-hydrogels are more effective 357 
in delaying the dissolution of the antioxidant in aqueous media than their chitosan counterparts.  358 
359 
INSERT FIGURE 5 ABOUT HERE 360 
361 
One of the most common semi-empirical models used to describe the release kinetics of 362 
bioactive molecules from delivery systems is the Peppas-Sahlin equation (Siepmann et al., 363 
2012), which takes into account the combination of Fickian (diffusion) and non-Fickian 364 
(polymer relaxation) release mechanisms. Thus, this model was used to fit the first points of the 365 
experimental data (up to 10 h), when the sink assumption is valid (Ritger & Peppas, 1987). Table 366 
2 shows the EGCG release kinetic parameters for both microencapsulation matrices in the MES 367 
aqueous food simulant according to the Peppas-Sahlin equation, assuming a spherical 368 
morphology (i.e. aspect ratio of 1) for the spray-dried micro-hydrogels and hence a Fickian 369 
diffusional exponent (m) of 0.425. 370 
371 
Table 2. EGCG release kinetic parameters (ki) and the linear correlation coefficients (R2) 372 
k1 (h-0.425) k2 (h-0.850) R2
Spray-dried Gel+EGCG 0.51±0.06 -0.12±0.02 0.996
Spray-dried Ch+EGCG 0.82±0.01 -0.21±0.01 0.996
373 
Both spray-dried matrices exhibited higher absolute values for k1 than for k2. Given that 374 
the first term of the Peppas-Sahlin equation (k1) is related to the contribution of the diffusion 375 
phenomenon to the overall release kinetics, and the second term (k2) accounts for the case-II 376 
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transport or relaxational phenomenon (Siepmann et al., 2012), the values in Table 2 suggest that 377 
the predominant release mechanism for these micro-hydrogels was a diffusion phenomenon. 378 
These results are in good agreement with those previously reported for EGCG-loaded gelatin 379 
microparticles obtained by electrospraying (Gómez-Mascaraque et al., 2015). The negative 380 
values obtained for k2 in both cases indicated that the swelling (or relaxation) of the polymeric 381 
matrices impeded the EGCG release in the initial burst release phase, due to the fast solvent 382 
uptake. The Peppas-Sahlin model also confirmed the faster EGCG release kinetics from the Ch 383 
hydrogels than from the Gel matrix, which could in part be attributed to their smaller particle 384 
size and consequent higher specific area, besides the intrinsic differences in the release 385 
mechanisms from both matrices. 386 
Even though the release was slower from the gelatin matrix, it was still relatively fast for 387 
these capsules to be directly applied to beverage foods, as the antioxidant molecule would be 388 
released during their storage. Rather, they would be more appropriate for the formulation of dry 389 
food products, which may require processing as a liquid or humid paste for a limited time but 390 
dried before storage, such as pastry or bakery products. 391 
392 
3.3. Antioxidant activity of EGCG-loaded micro-hydrogels 393 
The radical scavenging activity of both encapsulated and free EGCG was assessed by 394 
means of the ABTS•+ decolourization assay to ascertain whether the microencapsulation process 395 
had an impact on the antioxidant activity of the bioactive. There were no significant differences 396 
between the inhibition of the absorbance caused by the solvent blank and the two unloaded 397 
hydrogels (cf. Table 3), so the antioxidant activity of the matrices was indeed neglected. The 398 
RSA of the encapsulates was thus attributed only to the contribution of their EGCG content. 399 
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While no significant differences were found between the RSA of the gelatin encapsulates and the 400 
free EGCG, suggesting that the antioxidant activity of the bioactive was fully retained during the 401 
encapsulation process, the chitosan encapsulates showed a lower RSA than EGCG in its free 402 
form, supporting the lower encapsulation observed when chitosan was used as the encapsulating 403 
matrix. In fact, the antioxidant activities measured are in close agreement with encapsulation 404 
efficiencies estimated from the infrared spectra of the materials, as the gelatin micro-hydrogels 405 
retained 97% of the antioxidant activity of free EGCG, whereas chitosan encapsulates showed 406 
only 84% of its RSA. 407 
408 
Table 3. Antioxidant activity of free and encapsulated EGCG (theoretical EGCG concentration: 0.25 409 
mM), together with solvent and matrices blanks 410 
411 
Sample RSA (%) Standard deviation (%)
Solvent 3.2 a 0.3
Spray-dried Gel 2.8 a 0.3
Spray-dried Ch 2.4 a 1.1
EGCG 26.9 b 0.9
Spray-dried Gel+EGCG 26.0 b 2.4
Spray-dried Ch+EGCG 22.7 c 1.0
Different letters (a-c) within the same column indicate significant differences among the samples 412 
413 
3.4. In-vitro GI digestion and bioaccessibility assessment 414 
Although microencapsulation has proven to be efficient in preventing degradation of 415 
bioactive substances, it can also have an impact on their bioaccessibility (Roman et al., 2012). 416 
Thus, the assessment of the bioaccessibility of the encapsulated functional ingredients is of 417 
outmost importance in the design of novel functional foods, given that the Regulation (EC) 418 
1924/2006 on nutrition and health claims made on foods declares (in Section 15) that “In order to 419 
ensure that the claims made are truthful […] The substance should also be available to be used 420 
by the body” (Commission, 2006). One of the most simple definitions of bioaccessibility states 421 
that it is “the fraction of a compound that is released from its matrix in the gastrointestinal tract 422 
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and thus becomes available for intestinal absorption” (Fernández-García, Carvajal-Lérida, & 423 
Pérez-Gálvez, 2009), that is, “the fraction that is soluble in the gastrointestinal environment” 424 
(Cardoso, Afonso, Lourenço, Costa, & Nunes, 2015).  425 
Thus, knowledge about the bioaccessibility of EGCG encapsulated in gelatin or chitosan 426 
microcapsules is crucial to assess the suitability of these matrices as carriers for the bioactive 427 
compound in functional foods, but this information is scarce in the literature. Therefore, a 428 
bioaccessibility assessment was carried out in this work for the prepared microparticles. For this 429 
purpose, free and encapsulated EGCG were subjected to static in-vitro GI digestion and the 430 
soluble fraction of the digestas (i.e. the supernatant obtained after centrifugation) was analyzed 431 
by means of the ABTS•+ assay, which provided an indirect estimation of the EGCG content 432 
released from the matrix during digestion. The unloaded spray-dried micro-hydrogels, as well as 433 
blank samples (water) were also digested in order to disregard possible contributions of the 434 
encapsulation matrices and/or the enzymes added during digestion to the total antioxidant 435 
activity of the digestas. The value of RSA obtained for the digestas of the unloaded hydrogels 436 
and the blanks were then substracted from the RSA of the corresponding EGCG-containing 437 
digestas in order to take into account only the contribution of their EGCG content to their total 438 
antioxidant activity. The results are summarized in Table 4. 439 
440 
Table 4. Antioxidant activity of supernatants from gastric and duodenal digestas 441 
Sample RSA (%) of gastric digesta(*) 
RSA (%) of 
duodenal digesta 
EGCG 84 ± 8 a 52 ± 5 a
Spray-dried Gel+EGCG 23 ± 2 b 36 ± 3 b
Spray-dried Ch+EGCG 15 ± 3c 5 ± 2 c
 (*) The supernatant from the gastric digesta was diluted 2-fold before analysis, as the as-prepared samples 442 
provided a complete inhibition of the absorbance of ABTS•+ at 734nm. Different letters (a-c) within the same 443 
column indicate significant differences among the samples 444 
445 
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The RSA of the digestas of free EGCG and, consequently, its bioaccessibility, was 446 
significantly higher than the value obtained for encapsulated EGCG, suggesting that only part of 447 
the EGCG content was released from the microcapsules during in-vitro GI digestion, while free 448 
EGCG was already completely dissolved in water before digestion. This resulted in the partial 449 
degradation of free EGCG, as observed from the decrease in the antioxidant activity after the 450 
duodenal phase, while an increase in this antioxidant activity was observed for the soluble 451 
fraction of digested EGCG-loaded Gel microcapsules during digestion. Therefore, even though 452 
this fraction only represented the 27% of the value obtained for free EGCG after the gastric 453 
phase, it increased up to a 68% of the activity of free EGCG after the duodenal phase. These 454 
values are consistent with the EGCG release profile obtained for the gelatin matrix in an aqueous 455 
buffer (cf. Figure 5). From these results it was seen that around 50% of the EGCG content was 456 
released in MES after 3.3 hours. Given that digestion lasted 4 hours and that digestive enzymes 457 
were present in the simulated fluids, plus differences in the pH and ionic strength, and a slightly 458 
higher temperature, a release of a 68% of the EGCG content during digestion was in good 459 
agreement with the release results obtained.  460 
To further confirm these results, the supernatant of the digestas of EGCG-loaded Gel 461 
micro-hydrogels were analyzed by HPLC-MS. The mass spectrum of EGCG is shown in 462 
Supplementary Figure S2. The HPLC-MS experimental results obtained from the encapsulates 463 
followed the same trend as in the antioxidant studies, i.e. a greater difference in EGCG content 464 
was observed after the gastric phase, while only slight differences were observed in the digestas 465 
from the free and Gel encapsulated EGCG after the duodenal phase (cf. Supplementary Figure 466 
S3).  467 
468 
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INSERT FIGURE 6 ABOUT HERE 469 
470 
Interestingly, the mass spectra shown in Figure 6 suggested that after the gastric phase, 471 
the amount of dimer EGCG (m/z 915) in the digesta obtained from free EGCG was greater than 472 
in the Gel-encapsulated counterpart, where the monomeric compound (m/z 457) was most 473 
abundant. It is important to emphasize that while catechin monomers are readily absorbed in 474 
human subjects and animals, there are controversies about the bioavailability of oligomeric 475 
forms (Serra et al., 2010) thus suggesting that encapsulation could improve bioavailability by 476 
hindering the formation of oligomeric species.  477 
At the end of the intestinal digestion process, there was a marked decrease in the amount 478 
of EGCG which, in agreement with previous studies, showed that the major degradation of 479 
EGCG occurs in intestinal fluids (Serra et al., 2010).  480 
Regarding the bioaccessibility of EGCG microencapsulated in Ch, it was considerably 481 
lower than for the protein matrix. These results were unexpected considering the faster release of 482 
EGCG in aqueous media from the polysaccharide than from gelatin. However, they could be 483 
explained in light of the pH-responsive behavior of Ch hydrogels (Lim et al., 2014). In fact, the 484 
short oral phase of the digestion, although frequently disregarded in many studies (Minekus et 485 
al., 2014), seemed to be crucial for assessing the bioaccessibility of EGCG encapsulated in Ch. 486 
The neutral pH of the simulated salivary fluid would have neutralized the previously protonated 487 
amino groups of spray-dried Ch (as a consequence of its processing in acetic acid), favoring the 488 
formation of strong intra- and intermolecular interactions through hydrogen bonding (possibly 489 
involving the bioactive molecule) which are characteristic of Ch and are the main reason for the 490 
poor solubility of this polysaccharide in aqueous media (Filion, Lavertu, & Buschmann, 2007). 491 
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This neutralization of the Ch molecules would have hindered swelling of the particles and release 492 
of their EGCG contents. Previous studies had observed that neutralization of chitosan 493 
membranes prepared from acetic acid solutions triggered a molecular rearrangement of its 494 
polymer chains, modifying its physico-chemical properties and swelling behavior (Campos, 495 
Nogueira Campos, Ferreira Grosso, Cárdenas, & Inocentinni Mei, 2005). In order to confirm this 496 
neutralization during the oral phase, spray-dried Ch was subjected to the neutral pH found in the 497 
salivary solution and dried under vacuum. The bands in the 1800 Ð 1500 cm-1 region of the 498 
infrared spectrum of the resulting sample shifted back to the profile exhibited by the raw 499 
chitosan (cf. Figures S4 and S5 in the Supplementary material), thus supporting our hypothesis. 500 
With the aim of confirming that the differences observed in Table 4 were attributable to a 501 
lack of EGCG release from the capsules during digestion, the duodenal digestas (including the 502 
insoluble fraction) were subjected to treatment with acetic acid (20% v/v) and vigorous agitation 503 
during 4 hours, with the aim of dissolving the encapsulation structures. The treated digestas were 504 
then subjected to the ABTS+ assay, observing no significant differences between the RSA 505 
corresponding to free EGCG and both encapsulated EGCG samples (cf. Table S1 in the 506 
Supplementary material). Hence, the presence of the antioxidant compound in the insoluble 507 
fraction of the duodenal digestas of the encapsulates was corroborated. 508 
Comparing both matrices, although the bioaccessibility of EGCG decreased upon 509 
microencapsulation in both cases, it was significantly higher for Gel than for Ch, so the protein 510 
was considered to be a more suitable encapsulation matrix than the polysaccharide. Moreover, as 511 
commented on above, although a greater bioaccessibility was observed, the bioavailability of 512 
free EGCG during digestion might be compromised by the formation of oligomeric species, as 513 
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deduced from the mass spectra in Figure 6, which was much more limited when EGCG was 514 
encapsulated within the developed Gel micro-hydrogels. 515 
516 
3.5. Protection ability of spray-dried gelatin micro-hydrogels517 
As gelatin proved to be a more adequate matrix for the encapsulation of EGCG than 518 
chitosan, not only exhibiting higher encapsulation efficiencies and, thus, higher retention of the 519 
antioxidant activity, but also a more delayed EGCG release in aqueous solution and higher 520 
bioaccessibility of the bioactive after digestion, this matrix was selected to carry out an in-vitro521 
degradation test. This test was also based on the ABTS+ decolorization assay and was used to 522 
compare the degradation profiles of free and gelatin-encapsulated EGCG in PBS, by monitoring 523 
the decrease in their RSA value with time after dissolution or suspension in this medium.  524 
Hence, solutions of EGCG (5 mM) and suspensions of EGCG-loaded gelatin micro-525 
hydrogels (theoretical EGCG concentration also 5 mM) in PBS were prepared. The fast 526 
degradation of EGCG upon dissolution in this buffer could be visually observed by a change in 527 
color from a light pink to an intense yellowish color, as seen in previous work (Gómez-528 
Mascaraque et al., 2015). After different degradation periods, the samples in PBS were diluted 529 
20-fold with acetic acid 20% v/v to stop the degradation process by lowering the pH of the 530 
medium, and to facilitate the complete dissolution of the Gel micro-hydrogels. The RSA of the 531 
resulting solutions was then calculated by means of the ABTS+ assay and the results are shown 532 
in Figure 7.     533 
534 
INSERT FIGURE 7 ABOUT HERE 535 
536 
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Free EGCG experienced a rapid loss of antioxidant activity. After 4 days, it had lost 537 
almost one third of its initial activity, while no significant loss was observed in the RSA of the 538 
EGCG-loaded gelatin capsules within that time period. The RSA only slightly decreased after 10 539 
days in PBS. These results suggest that the encapsulation of EGCG in gelatin micro-hydrogels 540 
by the spray-drying technique could effectively protect EGCG from degradation in slightly 541 
alkaline solutions, in which free EGCG is highly unstable (Barras et al., 2009; Li et al., 2009). 542 
543 
INSERT FIGURE 8 ABOUT HERE 544 
545 
An HPLC-MS/MS analysis was carried out to confirm these results. As shown in Fig. 546 
8A, after 24 hours in PBS, the percentage of EGCG considerably decreased for the free (non-547 
encapsulated) bioactive. In contrast, the stability was significantly increased when EGCG was 548 
incorporated in the gelatin micro-hydrogels since just slight changes were observed in the 549 
recovery of EGCG after 24 hours (cf. Fig. 8B and Supplementary Figure S6 for more details). 550 
Moreover, as observed from the chromatograms of non-encapsulated EGCG in Figure 8, 551 
the decrease in the EGCG peak was accompanied by the appearance of a peak at 2.1 minutes 552 
which increased with incubation time and that corresponded to EGCG degradation products as 553 
shown in Supplementary Figure S7 (cf. supporting information for a more in-depth analysis). 554 
Since EGCG is a potent anti-oxidant, it tends to be oxidized within biological environment, 555 
leading to lower bioavailability and short half-life limiting its therapeutic efficiency (Mizooku, 556 
Yoshikawa, Tsuneyoshi, & Arakawa, 2003). Interestingly, this peak was absent in the 557 
chromatograms from the EGCG encapsulated within the gelatin micro-hydrogels, thus 558 
confirming the protection ability of the structures developed. 559 
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560 
4. Conclusions 561 
Spray-dried micro-hydrogels based on gelatin and chitosan were proposed as 562 
encapsulating matrices for the model flavonoid EGCG. Although the polysaccharide gave rise to 563 
smaller microparticles with narrower size polydispersity than the protein, the latter achieved 564 
higher microencapsulation efficiencies (95% ± 6%) than the former (82% ± 9%), as estimated by 565 
infrared spectroscopy. These results were confirmed by ABTS+ assays, which corroborated that 566 
the gelatin micro-hydrogels retained 97% of the antioxidant activity of free EGCG, while 567 
chitosan showed only 84% of its radical scavenging activity. The TGA profiles of the samples 568 
suggested that microencapsulation was successful in stabilizing the bioactive thermally, as only 569 
the degradation steps attributed to the matrices were detected. The release of EGCG from the 570 
spray-dried particles when suspended in slightly acidic aqueous solution was faster from the 571 
chitosan matrix, so gelatin was more effective in delaying the solubility of the flavonoid in this 572 
medium. Furthermore, the bioaccessibility of EGCG after digestion was higher when 573 
microencapsulated in gelatin than in chitosan, as the latter pH-sensitive micro-hydrogel 574 
precluded the release of the bioactive after being neutralized in the basic mouth conditions. 575 
Moreover, encapsulation in gelatin hindered EGCG dimer formation, which may also have an 576 
impact from the bioavailability viewpoint. The overall results suggested that gelatin-based 577 
micro-hydrogels are more adequate as encapsulation matrices for flavonoids than chitosan for 578 
application in the development of functional foods. The capability of gelatin to stabilize EGCG 579 
against degradation in slightly alkaline aqueous solution was also demonstrated, thus broadening 580 
the potential for food incorporation. 581 
582 
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Figure Captions 742 
Figure 1. Schematic chemical structures of raw materials: a) gelatin, b) chitosan and c) EGCG 743 
Figure 2. SEM images of spray-dried particles 744 
Figure 3. Particle size distributions of spray-dried samples 745 
Figure 4. Infrared spectra of commercial EGCG and spray-dried materials 746 
Figure 5. EGCG release profiles from the spray-dried micro-hydrogels. The inset shows an 747 
extended release profile up to 350 hours. 748 
Figure 6. Mass spectra of free (left) and Gel-encapsulated EGCG (right) before digestion (A) 749 
and after in-vitro gastric (B) and intestinal digestion (C). 750 
Figure 7. Radical scavenging activity of free EGCG and EGCG-loaded gelatin micro-hydrogels 751 
after different degradation periods in PBS. Asterisk (*) depicts a significant difference between 752 
results corresponding to free EGCG with respect to encapsulated EGCG (p<0.05). 753 
Figure 8. Total ion chromatogram of (A) free-EGCG and (B) Gel-EGCG in PBS at different 754 
incubation times (0 h, 2 h and 24 h).  755 
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HIGHLIGHTS 784 
 Gelatin retained the antioxidant activity of EGCG more effectively than chitosan 785 
 Gelatin delayed the solubility of EGCG in aqueous medium to a greater extent 786 
 Bioaccessibility of EGCG was greater when encapsulated in gelatin than in chitosan 787 
 Microencapsulation in gelatin hindered EGCG dimer formation during digestion 788 
 Gelatin stabilized EGCG against degradation in alkaline aqueous solution 789 
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Results and Discussion 804 
Thermal stability of the microparticles 805 
Figure S1 shows that three main stages were observed in all the TG curves. Due to the 806 
hygroscopic character of the biopolymers, an initial stage corresponding to the loss of water was 807 
observed. The second stage occurred at temperatures of maximum degradation rate close to 808 
300ºC for both the polysaccharide and the protein. This thermo-oxidative degradation has been 809 
associated to deacetylation and depolymerisation processes in Ch1, and to protein chain rupture 810 
and peptide bonds breakage in Gel2. The last stage, observed between 400ºC and 600ºC, has 811 
been related to the thermal destruction of the pyranose ring and the oxidative decomposition of 812 
residual carbon in Ch3, and to thermal decomposition of the polymer networks in Gel4. 813 
The TG curves of the spray-dried Ch particles showed a noticeable decrease in the thermal 814 
stability of the polysaccharide after processing, both in the presence and in the absence of 815 
antioxidant. This could be mainly attributed to the presence of residual solvent molecules which 816 
modified the thermal stability of the biopolymer5. 817 
Thermostability changes are also observed for processed Gel. In this case, the main degradation 818 
stage exhibits two different maxima which might be attributed to two different structures or 819 
morphologies. This observation is consistent with the existence of a few apparently hollow, thin-820 
walled structures together with more compact rounded particles in these samples, as observed by 821 
SEM. Our group had observed similar changes towards the appearance of two maxima in the 822 
main stage of the TG curves of Gel when the protein was subjected to electrospraying, where 823 
two different morphologies could be differentiated too (particles and residual fibrils)6.   824 
It is worth noting that the water loss during the first stage also changed after spray-drying the 825 
biopolymers. While the raw materials experienced a weight loss which extended well above 826 
44
100ºC, especially in the case of gelatin, all spray-dried samples lost the water they contained 827 
before reaching 100ºC. This suggests that only absorbed water was present in the spray-dried 828 
samples, and that structural water was removed during processing due to the rapid drying of the 829 
materials.      830 
831 
832 
833 
834 
835 
836 
837 
838 
839 
840 
841 
Figure S1. DTG curves of raw matrices and spray-dried particles of Ch (top) and Gel (bottom) 842 
843 
In-vitro GI digestion and bioaccessibility assessment 844 
Supplementary Figure 2 showed that, according to previous studies7 EGCG gave a high intensity 845 
of the deprotonated molecular ion, [M-H]-, at m/z 457 in negative ESI analyses. Besides the 846 
deprotonated molecular ion, two adduct ions at m/z 915 [2M-H]-, m/z 537 [M-H+80]- and m/z 847 
493 M-H+36]- were obtained in the mass spectrum. The adduct ion [2M-H]- was formed 848 
because the effect of the hydrogen bond. The adduct [M-H+80]- was formed from EGCG with 849 
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the mobile phase modifier, formic acid. Finally, the adduct ion at m/z 493, showed the chlorine 850 
adduct ion. 851 
852 
853 
854 
855 
856 
857 
858 
859 
860 
861 
Figure S2. Information dependant acquisition (IDA) experiment of EGCG in PBS sample (t=0h) 862 
(A) Total Ion Chromatogram (B) EGCG spectrum and compound identification. 863 
864 
Figure S3 shows the chromatograms of free and Gel-encapsulated EGCG after in-vitro gastric 865 
and intestinal digestion. As observed from this Figure, there was an excellent match between the 866 
HPLC-MS experimental results and the antioxidant studies after the gastric phase, being the 867 
percentage of decrease in antioxidant activity and total ion count similar (around 60%) between 868 
the free and encapsulated EGCG. It should be stressed that the low signal observed after the 869 
intestinal phase was ascribed to the low concentration of EGCG in the extract at the end of the 870 
simulated digestion process, but the mass spectra confirmed the presence of the bioactive as 871 
shown in Figure 6 of the manuscript. 872 
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Figure S3: Information dependant acquisition (IDA) experiment of EGCG (A) TIC of gastric 882 
digesta extract (A1 corresponding to free-EGCG and A2 to Gel-encapsulated EGCG extracted 883 
chromatogram) and (B) TIC of intestinal digesta extract.884 
885 
In this work it was also observed that the bioaccessibility of EGCG in the chitosan micro-886 
hydrogels was very low, fact which was ascribed to the neutralization of the encapsulating 887 
matrix in the simulated salivary fluid. To confirm this hypothesis, spray-dried Ch was subjected 888 
to the neutral pH found in the salivary solution and dried under vacuum. Figure S4 shows that 889 
the bands in the 1800 Ð 1500 cm-1 region of the infrared spectrum of the resulting sample shifted 890 
back to the profile exhibited by the raw chitosan. 891 
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Figure S4. Spray-dried chitosan before (as prepared) and after contacting the simulated salivary 903 
fluid (neutralized). 904 
905 
Protection ability of spray-dried gelatin micro-hydrogels 906 
Basic pH is known to affect EGCG stability and, thus, the degradation of free EGCG and gelatin 907 
encapsulated EGCG was studied after incubating them in PBS solution during 2 and 24 hours. 908 
To determine the recovery, solutions (5 mM) of EGCG in PBS and suspensions of EGCG-loaded 909 
gelatin micro-hydrogels in PBS with theoretical EGCG concentrations of 5 mM were and the 910 
samples were incubated during 2 and 24 hours and analyzed through HPLC-MS/MS. The 911 
recovery of EGCG was determined considering 100% recovery of free EGCG at the initial time. 912 
Figure S5 shows that while a marked recovery decrease was observed for the non-encapsulated 913 
compound after 24 hours, EGCG concentration only marginally decreased when encapsulated 914 
within gelatin, thus highlighting the protection ability in this medium of the developed micro-915 
hydrogels.    916 
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Figure S5: Stability studies of EGCG in PBS medium after 2 and 24 hours incubation.929 
930 
Although the main goal of HPLC-MS analysis was not to identify the degradation products of 931 
EGCG, particular attention was given to the degradation of free EGCG in PBS to explain its 932 
antioxidant capacity since despite the significant decrease in its content after 24 hours of 933 
incubation in PBS, a high antioxidant activity remained. Therefore, the peak arising at 2.1 934 
minutes in the chromatograms of the non-encapsulated bioactive was characterized and the 935 
results are shown in Figure S6. Since the QqTOF system used in this study has the capacity to be 936 
used for screening non-target and/or unknown compounds, the identification of molecules 937 
responsible of this signal was carried out.  938 
As it can be observed in Figure S6, the mass spectrum of this peak exhibits the ions m/z 455 and 939 
m/z 473, which increased along incubation time. After an in-depth and exhaustive review of the 940 
published literature about EGCG degradation, these ions were identified as O-methyl 941 
49
derivatives8. Since EGCG is a potent antioxidant, it tends to be oxidized within biological 942 
environments, thus leading to lower bioavailability and short half-life limiting its therapeutic 943 
efficiency9. Unfortunately, and as far as we know, no previous studies have been published 944 
regarding the antioxidant activity of EGCG O-methyl derivatives. However, Dueñas et al.10945 
evaluated the antioxidant capacity of O-methylated metabolites of catechin, epicatechin and 946 
quecertin, concluding that despite the relative decrease of antioxidant capacity of these 947 
metabolites, they still presented relatively high antioxidant activity.  948 
949 
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Figure S6. Information dependant acquisition  (IDA) experiment of EGCG degradation after one 956 
day in PBS  (A) Total Ion Chromatogram at different times (0 hour, 2 hours and 24 hours); (B) 957 
EGCG Spectrum at 2 hours and (C) EGCG Spectrum at 24 hours corresponding to 2.1 minutes 958 
peak. 959 
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